Poly(ADP‐ribose) polymerase (PARP) inhibitors for the ...
A phase 3 trial tested niraparib vs. placebo in 553 patients with recurrent ovarian cancer, stratified by gBRCA mutation status. Primary outcome was PFS, with secondary outcomes including OS and safety. The study was randomized, double-blind, and placebo-controlled, showing low risk of bias across assessed domains.
Reference News
Poly(ADP‐ribose) polymerase (PARP) inhibitors for the ...
A phase 3 trial tested niraparib vs. placebo in 553 patients with recurrent ovarian cancer, stratified by gBRCA mutation status. Primary outcome was PFS, with secondary outcomes including OS and safety. The study was randomized, double-blind, and placebo-controlled, showing low risk of bias across assessed domains.